- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04720196
Analgesic Effect of rTMS in Vasculitic Neuropathy
March 7, 2022 updated by: Jakub Antczak, Jagiellonian University
Analgesic Effect of Repetitive Transcranial Magnetic Stimulation in Painful Vasculitic Neuropathy
Vasculitic neuropathy (VN) results from inflammation and destruction of the walls of predominantly small vessels with subsequent ischemic damage of peripheral nerves.
VN is painful in vast majority of patients and the pain is intractable with pharmacotherapy in about 40% of cases.
Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies.
The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves.
Neural damage may or may not coexist with the damage of other organs.
Examples of conditions associated with VN include diabetes, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss), granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, systemic lupus erythematosus and others.
VN is painful in about 80% of patients of whom 40% suffer from the pain intractable with pharmacological therapy.
Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity.
In this method, series of magnetic stimuli are delivered to the cerebral cortex, where they turn to electric current and depolarize repetitively the targeted neurons.
If the stimulation is repeated during subsequent days it is capable to modify the activity of targeted cortical area for weeks or even months and by this way to achieve therapeutic effect.
rTMS is widely regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies.
The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jakub M Antczak, MD
- Phone Number: +48 795 421 153
- Email: [email protected]
Study Contact Backup
- Name: Gabriela G Rusin, MD
- Phone Number: +48 601 661 607
- Email: [email protected].edu.pl
Study Locations
-
Poland
-
-
Kraków, Poland, 31503
- Recruiting
- Jagiellonian University Medical College, Department of Neurology
-
Contact:
- Jakub M Antczak, MD
- Phone Number: +48 795 421 153
- Email: [email protected]
-
Contact:
- Gabriela Rusin, MD
- Phone Number: +48 601 661 607
- Email: [email protected]
-
Sub-Investigator:
- Justyna Brączyk, MS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of vasculitic neuropathy
- Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week
- Score of 30 milimeter or more on the 100 milimeter visual analog scale of pain intensity at inclusion
Exclusion Criteria:
- Severe depression
- Personality disorders and other psychiatric conditions, which could disturb the participation in the study
- Cognitive deficits, which could disturb the participation in the study
- Contraindications for rTMS as listed by the Guidelines of the International Federation of Clinical Neurophysiology (Rossi et al. 2009) i.e. seizure in the past, epilepsy, presence of magnetic material in the reach of magnetic field, pregnancy, likelihood to get pregnant, intracranial electrodes, cardiac pacemaker or intracardiac lines, frequent syncopes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham repetitive transcranial magnetic stimulation
Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
|
Sham stimulation to mimic the high frequency rTMS over the primary motor area.
|
Experimental: Active repetitive transcranial magnetic stimulation
10 hertz (Hz) rTMS will be administered over the primary motor area.
Therapy will include 5 daily sessions (on consecutive week days).
In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
|
High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numeric Pain Severity Scale after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Total score 10, with higher scores representing more severe pain.
Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Numeric Pain Severity Scale First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Total score 10, with higher scores representing more severe pain.
Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Numeric Pain Severity Scale Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Total score 10, with higher scores representing more severe pain.
Change from baseline score in the Numeric Pain Severity Scale to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Visual Analog Scale of Pain Severity
Time Frame: Through study completion, an average of 10 weeks
|
An analog scale of the length of 100 milimeter.
Total score of 100, with higher scores representing more severe pain.
Change through the study.
|
Through study completion, an average of 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Anxiety and Depression Scale after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Total score 64, with higher scores representing more severe depression.
Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Hospital Anxiety and Depression Scale First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Total score 64, with higher scores representing more severe depression.
Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Hospital Anxiety and Depression Scale Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Total score 64, with higher scores representing more severe depression.
Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
36-Item Short Form Health Survey after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Total score, range 0 to 800, with lower values representing a worse outcome.
Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
36-Item Short Form Health Survey First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Total score, range 0 to 800, with lower values representing a worse outcome.
Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
36-Item Short Form Health Survey Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Total score, range 0 to 800, with lower values representing a worse outcome.
Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Total score, range 0 to 100, with lower values representing a worse outcome.
Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Total score, range 0 to 100, with lower values representing a worse outcome.
Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Total score, range 0 to 100, with lower values representing a worse outcome.
Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Assessment of pain threshold to electric stimuli after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful.
Change from baseline pain threshold to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Assessment of sensory threshold to electric stimuli after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation.
Change from baseline sensory threshold to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Assessment of pain threshold to electric stimuli First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful.
Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Assessment of sensory threshold to electric stimuli First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation.
Change from baseline sensory threshold to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Assessment of pain threshold to electric stimuli Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful.
Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Assessment of sensory threshold to electric stimuli Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation.
Change from baseline sensory threshold to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Assessment of cold sensation threshold to cold stimuli after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold.
Change from baseline cold sensation threshold to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Assessment of pain threshold to cold temeprature stimuli after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful.
Change from baseline pain threshold to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Assessment of cold sensation threshold to cold temeprature stimuli First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold.
Change from baseline cold sensation threshold to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Assessment of pain threshold to cold temeprature stimuli First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful.
Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Assessment of cold sensation threshold to cold temeprature stimuli Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold.
Change from baseline cold sensation threshold to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Assessment of pain threshold to cold temeprature stimuli Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful.
Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Assessment of warmth sensation threshold to warm temeprature stimuli after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth.
Change from baseline warmth sensation threshold to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Assessment of pain threshold to warm temeprature stimuli after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful.
Change from baseline pain threshold to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Assessment of warmth sensation threshold to warm temeprature stimuli First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth.
Change from baseline warmth sensation threshold to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Assessment of pain threshold to warm temeprature stimuli First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful.
Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Assessment of warmth sensation threshold to warm temeprature stimuli Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth.
Change from baseline warmth sensation threshold to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Assessment of pain threshold to warm temeprature stimuli Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful.
Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Bilateral Dynamometric Assessment of the strength of the index finger flexion after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Change from baseline strength of the index finger flexion to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Bilateral Dynamometric Assessment of the strength of the foot extension after rTMS
Time Frame: Before rTMS, immediately after (on same day) finishing rTMS.
|
Change from baseline strength of the foot extension to the measurement taken after finishing rTMS.
|
Before rTMS, immediately after (on same day) finishing rTMS.
|
Bilateral Dynamometric Assessment of the strength of the index finger flexion First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Change from baseline strength of the index finger flexion to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Bilateral Dynamometric Assessment of the strength of the foot extension flexion First Follow Up
Time Frame: Before rTMS, two weeks after finishing rTMS
|
Change from baseline strength of the foot extension to the measurement taken two weeks after finishing rTMS.
|
Before rTMS, two weeks after finishing rTMS
|
Bilateral Dynamometric Assessment of the strength of the index finger flexion Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Change from baseline strength of the index finger flexion to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Bilateral Dynamometric Assessment of the strength of the foot extension Second Follow Up
Time Frame: Before rTMS, four weeks after finishing rTMS
|
Change from baseline strength of the index foot extension to the measurement taken four weeks after finishing rTMS.
|
Before rTMS, four weeks after finishing rTMS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Justyna Brączyk, MS, Jagiellonian University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 25, 2021
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
June 1, 2023
Study Registration Dates
First Submitted
January 16, 2021
First Submitted That Met QC Criteria
January 18, 2021
First Posted (Actual)
January 22, 2021
Study Record Updates
Last Update Posted (Actual)
March 8, 2022
Last Update Submitted That Met QC Criteria
March 7, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JagiellonianU63
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
After completing the study, the age and gender of participants as well as the scores and results of all outcome measurements made at baseline, after rTMS, at the first and at the second follow up will be made available to other researchers on request.
IPD Sharing Time Frame
The data will become available after the study results will be published.
IPD Sharing Access Criteria
On request send by e-mail: [email protected]
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasculitic Neuropathy
-
NCT04720196RecruitingConditions: Vasculitic Neuropathy
-
NCT03584022Enrolling by invitationConditions: Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Vasculitic Neuropathy (Disorder), Amyloidosis, Hereditary Neuropathy, Sarcoid Neuropathy
Clinical Trials on Active repetitive transcranial magnetic stimulation
-
NCT05723588Not yet recruiting
-
NCT05651334Recruiting
-
NCT05295498RecruitingConditions: Peripheral Neuropathy
-
NCT04083144Active, not recruitingConditions: Tobacco Use Disorder, Smoking Cessation
-
NCT05599373RecruitingConditions: Schizophrenia, Negative Symptoms in Schizophrenia, Cognitive Impairment, Repetitive Transcranial Magnetic Stimulation, Dorsolateral Prefrontal Cortex
-
NCT04432493Active, not recruitingConditions: Opioid-use Disorder
-
NCT05502432CompletedConditions: Spinocerebellar Ataxia Type 3
-
NCT02426749CompletedConditions: Brain Injuries, Traumatic
-
NCT04720196RecruitingConditions: Vasculitic Neuropathy
-
NCT02611206CompletedConditions: Treatment Resistant Depression